Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Eptifibatide
Drug ID BADD_D00792
Description Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics.
Indications and Usage For treatment of myocardial infarction and acute coronary syndrome.
Marketing Status Prescription; Discontinued
ATC Code B01AC16
DrugBank ID DB00063
KEGG ID D06888
MeSH ID D000077542
PubChem ID 448812
TTD Drug ID D09ZIO
NDC Product Code 67457-631; 32861-0002; 16729-260; 36974-0068; 72078-026; 70436-026; 14403-0007; 70121-1003; 52958-402; 55150-218; 55150-220; 70436-162; 68225-005; 70436-163; 52958-128; 0338-9559; 16729-259; 14335-070; 70121-1002; 14335-071; 17478-902; 55150-219; 41524-0002; 52958-001; 25021-409; 62756-500; 25021-408; 0338-9558; 68225-006; 70436-027; 72078-025; 67457-630; 17478-903; 70860-303; 72078-027; 67457-629
Synonyms Eptifibatide | Epifibratide | Epifibatide | 7H-Pyrrolo(2,1-g)(1,2,5,8,11,14,17,20)dithiahexaazacyclotricosine-17-acetic acid, 3-(aminocarbonyl)-11-(4-((aminoiminomethyl)amino)butyl)docosahydro-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxo-, (3R,11S,17S,20S,25aS)- | Integrilin | Integrelin
Chemical Information
Molecular Formula C35H49N11O9S2
CAS Registry Number 188627-80-7
SMILES C1CC2C(=O)NC(CSSCCC(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC (=O)O)CCCCN=C(N)N)C(=O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Surgical and medical proceduresIntegrin alpha-IIbP08514Not Available10195947; 11447076; 11151063; 11425767
Surgical and medical proceduresIntegrin beta-3P05106T2645710195947; 11447076; 11151063; 11425767
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Headache17.14.01.001--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypotension24.06.03.002--
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Injection site reaction08.02.03.014; 12.07.03.015--
Injury12.01.08.004--Not Available
Liver disorder09.01.08.001--Not Available
Lymphoma16.20.01.001; 01.12.01.001--Not Available
Myocardial infarction24.04.04.009; 02.02.02.007--
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Non-Hodgkin's lymphoma16.35.01.001; 01.17.01.001--Not Available
Pain08.01.08.004--
Pericardial effusion02.06.01.002--
Phlebitis24.05.03.001; 12.02.01.002--
Pneumonia11.01.09.003; 22.07.01.003--Not Available
Pulmonary haemorrhage24.07.01.016; 22.02.04.003--
Rash23.03.13.001--Not Available
Renal failure20.01.03.005--Not Available
Retroperitoneal haemorrhage24.07.01.017; 07.07.02.002--
Shock24.06.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombophlebitis24.01.02.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Ventricular fibrillation02.03.04.008--
Ventricular tachycardia02.03.04.010--
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages